Seth van Voorhees - 16 Dec 2022 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: NRXP
Reported as of: 16 Dec 2022
Net transaction value: +$33,000
SEC form: 4
Accepted by SEC: 19 Dec 2022, 06:09:44 UTC
Prior SEC filing: 19 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Seth Van Voorhees

Key filing fact

Seth van Voorhees filed Form 4 for NRX Pharmaceuticals, Inc. (NRXP) on 19 Dec 2022.

Key facts

This page summarizes Seth van Voorhees's Form 4 filing for NRX Pharmaceuticals, Inc. (NRXP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 Dec 2022, 06:09.

Change

Previous filing in this sequence was filed on 19 Dec 2022.
Current net transaction value: +$33,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRXP transaction

Common Stock, par value $0.001 per share

Purchase

Transaction value: $33,000
Shares: +30,000
Change %: +184%
Price: $1.10
Shares after: 46,337
Date: 16 Dec 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.11. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.